Incivek Label Updated with Black Box Warning

Share this article:
INCIVEK (telaprevir) 375mg tablets by Vertex Pharmaceuticals
INCIVEK (telaprevir) 375mg tablets by Vertex Pharmaceuticals

Vertex Pharmaceuticals announced that the Incivek (telaprevir) label has been updated to include a boxed warning stating that fatal and non-fatal serious skin reactions have been reported in patients taking Incivek combination treatment. Some fatal cases have been reported in patients with progressive rash and systemic symptoms who continued to receive Incivek combination treatment after a serous skin reaction was identified.

In Phase 3 clinical trials, <1% of people who received Incivek combination treatment experienced a serious skin reaction. Rash and serious skin reactions were previously included in the Warnings and Precautions section of the label, but the boxed warning further emphasizes the importance of discontinuing treatment in the event of one of these reactions.

In addition, the Incivek label was updated to include additional information on the time to onset and management of anemia.

Incivek is a hepatitis C virus NS3/4A protease inhibitor indicated in chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin in patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have previously been treated with interferon-based therapy, including prior null responders, partial responders, and relapsers.

For more information call (877) 824-4281 or visit www.incivek.com.

Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Safety Alerts and Recalls

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs